Articles On Immutep (ASX:IMM)

Cancer-fighting biotech Immutep (ASX:IMM) has risen off 10-year-long lows after flagging a payment of $7.4m from British pharma giant GSK. Immutep shares got a 14 per cent boost to 2.5c, after closing at 2.2c on Friday. The share price has...

On Stockhead today, the disconnect between federal and state governments on coal, private equity deals are rising and an ‘avalanche’ is laying waste to lithium prices. But first, here’s what you need to know.   The day ahead Data Today the...

Shares in Immuron took a 17 per cent hit this morning after the company revealed its IMM-124E drug did not work in a trial with patients suffering from severe alcoholic hepatitis. Immuron (ASX:IMM), which is developing oral drugs for gut di...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

In this week’s recap of substantial holders, Australian Super became an substantial holder in Gage Roads Brewing (ASX: GRB), a prominent Sydney property magnate bought 16 per cent of Collaborate Corporation, and we look at a number of purch...

The benchmark index S&P/ASX 200 is trading at 6,665.7 on 10 July 2019 (AEST 01:58 PM), up 0.45%, while the S&P/ASX 200 Health Care Index is up 0.4% to 34,275.1. Let us discuss three healthcare stocks listed on ASX, along with their...

A company may require more funds over and above its retained earnings in order to expand its existing operations, develop new businesses, protect market share or buy another company. The requirement of the company can be fulfilled by either...

ASX-listed biotech Immutep has raised about $10 million in an equity deal through Bell Potter Securities. 

Australia is home to some of the top physicians as well as healthcare professionals. For more than 30 years, various companies across the globe have depended on the clinical trial in Australia and its capability to deliver timely results wi...

Immutep (ASX:IMM) has completed patient enrolment of the Phase 2b Active Immunotherapy PAClitaxel clinical trial in HER2-negative/ Hormone Receptor-positive (HR+) metastatic breast cancer.

The below-mentioned health care stocks have come up with significant updates today. Let’s take a quick look at these stocks. MGC Pharmaceuticals Ltd (ASX: MXC) The European based biopharma company, MGC Pharmaceuticals Ltd (ASX: MXC) has si...

The Australian Healthcare System is amongst the most inclusive in the world, and it offers a wide range of services right from catering to general and preventative health and treating more complex conditions in patients. The healthcare syst...

Sydney-based Immutep (ASX:IMM) has announced that the first patient in the INSIGHT-004 phase 1 clinical trial has been enrolled in Germany and has received the first dose of treatment.

06 Jun 2019 - Biotech company Immutep (ASX:IMM) reports that the first patient in the INSIGHT-004 Phase I clinical trial has received the first dose of treatment in Germany.